title: [Spironolactone inhibits hepatic sinusoid angiogenesis in rats with hepatic fibrosis].
abstract: OBJECTIVE
  To investigate the inhibitory effects of spironolactone against hepatic sinusoid angiogenesis in rats with hepatic fibrosis.
  
  
  METHODS
  Twenty-four male Wistar rats were randomly divided into sham-operated group, bile duct ligation (BDL) group, and BDL+SP group in which the rats received daily spironolactone injection (20 mg/kg) the day after BDL. Four weeks after the operation, the rats were sacrificed for examination of liver histology using Masson staining and the expression of vascular endothelial growth factor A (VEGF-A) mRNA in the liver using real-time quantitative PCR. Immunohistochemistry was used to detect the expression of von Willebrand factor (vWF) in the hepatic tissues.
  
  
  RESULTS
  Spironolactone significantly inhibited liver fibrogenesis in rats after BDL (METAVIR liver fibrosis scores 2.84∓0.44 vs 19.73∓3.54, P=0.00). Real-time PCR and immunohistochemistry showed that compared with BDL group, spironolactone treatment significantly inhibited the expression of VEGF-A mRNA (0.71∓0.12 vs 1.75∓0.15, P=0.00) and vWF (1.15∓0.09 vs 3.08∓0.17, P=0.00) in the liver. The expression of VEGF-A mRNA was highly correlated with the expression of vWF (r=0.890, P=0.000).
  
  
  CONCLUSIONS
  Spironolactone can inhibit hepatic sinusoid angiogenesis in rats with BDL-induced hepatic fibrosis by inhibiting the expression of VEGF-A.
authors.affiliation: Department of Emergency, Southern Medical University, Guangzhou, China. mylx99@163.com
authors.forename: Xu
authors.initials: X
authors.lastname: Li
authors.forename: Shuangming
authors.initials: S
authors.lastname: Cai
authors.forename: Zuowei
authors.initials: Z
authors.lastname: Ning
authors.forename: Yang
authors.initials: Y
authors.lastname: Li
authors.forename: Wenyong
authors.initials: W
authors.lastname: Zhang
authors.forename: Lili
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000818:Animals; D006503:Hepatic Veins / Q000473:pathology*; D008106:Liver Cirrhosis, Experimental / Q000378:metabolism / Q000473:pathology*; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D013148:Spironolactone / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
chemical_list: D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; D013148:Spironolactone